IPO - 60 DEGREES PHARMACEUTICALS, INC.

Add to your watchlist
Back to List of IPO Filings

Form Type: S-1

Filing Date: 2025-07-07

Corporate Action: Ipo

Type: New

Accession Number: 000121390025061842

Filing Summary: 60 Degrees Pharmaceuticals, Inc. is filing a registration statement with the SEC to offer up to 2,036,659 shares of common stock and various warrants for a public offering expected to commence after the effective date. The common stock and accompanying Series A-1 and A-2 Warrants have an offering price of $2.455 per share, based on the last sale price on July 2, 2025. The new warrants will be exercisable beginning on the effective date of stockholder approval. The company aims to raise capital to support general corporate purposes, including working capital. The offering will terminate on August 30, 2025, unless terminated earlier, and the offering price and terms were negotiated based on market conditions and company prospects. Notably, the company has recently executed a reverse stock split of its common stock at 1-for-5 and highlighted its mission to develop therapies for infectious diseases, expanding its pipeline including repositioning existing products for new indications. The company is also categorized as an emerging growth and smaller reporting company, allowing it to utilize reduced reporting requirements.

Additional details:

Company Name: 60 Degrees Pharmaceuticals, Inc.


State Incorporation: Delaware


Irs Employer Identification Number: 45-2406880


Address: 1025 Connecticut Avenue NW, Suite 1000 Washington, D.C. 20036


Agent Name: Geoffrey S. Dow


Agent Title: President and Chief Executive Officer


Agent Address: 1025 Connecticut Avenue NW, Suite 1000 Washington, D.C. 20036


Agent Phone: 202-327-5422


Placement Agent: H.C. Wainwright & Co., LLC


Number Of Shares Offered: 2,036,659


Warrant Type: Series A-1 and A-2


Exercise Price: $2.455


Form Type: DRS

Filing Date: 2025-06-06

Corporate Action: Ipo

Type: New

Accession Number: 000121390025052232

Filing Summary: 60 Degrees Pharmaceuticals, Inc. is filing a draft registration statement for a public offering of common stock and accompanying warrants. This registration is part of their strategy to raise capital for general corporate purposes including working capital. The company is classified as a smaller reporting and emerging growth company according to the Jumpstart Our Business Startups Act. The prospectus outlines their recent activities in the market, particularly the rebranding and repurposing of their malaria treatment product, Arakoda, and their plans to explore further therapeutic applications for chronic tick-borne diseases like Babesiosis using the active ingredient Tafenoquine. The registration statement remains confidential and has not been officially filed for public viewing, underscoring the ongoing preparation for market entry. The company has indicated that any sale of shares will happen promptly after the registration statement becomes effective, although no specific date has been set other than indications that market conditions will influence the timing of the offering.

Additional details:

Business Address: 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C. 20036


Agent For Service: Geoffrey S. Dow, President and Chief Executive Officer


Emerging Growth Company: true


Smaller Reporting Company: true


Reverse Stock Split Ratio: 1-for-5


Form Type: CORRESP

Filing Date: 2025-03-31

Corporate Action: Ipo

Type: New

Accession Number: 000121390025026133

Filing Summary: 60 Degrees Pharmaceuticals, Inc. is requesting the acceleration of their Registration Statement on Form S-1 (File No. 333-284983) to be declared effective on April 2, 2025, at 4:30 P.M. Eastern Time. The request is made pursuant to Rule 461 under the Securities Act of 1933. The company acknowledges its responsibility for the accuracy of disclosures regardless of any review or inaction by the SEC staff. They request to be notified of the effectiveness by contacting Ross D. Carmel, Esq.

Additional details:

Requested Date: 2025-04-02


Requested Time: 16:30


Contact Name: Ross D. Carmel


Contact Firm: Sichenzia Ross Ference Carmel LLP


Contact Phone: (212) 930-9700


Form Type: S-1/A

Filing Date: 2025-03-27

Corporate Action: Ipo

Type: Update

Accession Number: 000101376225003353

Filing Summary: 60 Degrees Pharmaceuticals, Inc. has filed an amended registration statement under the Securities Act of 1933 on March 27, 2025, indicating its intention to offer and sell up to 747,200 shares of its common stock. This filing includes a detailed prospectus related to the resale of common stock by selling stockholders, which includes 408,621 shares from January 2025 Common Warrants and 300,700 shares from February 2025 Warrants, among others. The document outlines the terms under which the shares may be sold, including pricing, the nature of the securities involved, and the responsibilities of both the company and the selling stockholders. The company also notes its status as an emerging growth and smaller reporting company, thereby complying with reduced public company reporting requirements. Furthermore, it elaborates on its primary product, Arakoda, approved for malaria prevention, and mentions ongoing development for additional therapeutic indications, particularly in infectious diseases. The document emphasizes that the registration statement's effectiveness is pending, highlighting risks and market opportunities associated with the company's products. Overall, this filing represents a significant step in the company's efforts to raise capital and expand its business initiatives.

Additional details:

Company Name: 60 Degrees Pharmaceuticals, Inc.


State Of Incorporation: Delaware


Address: 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036


Sequence Number: 1


Common Stock Par Value: $0.0001


Common Stock Total Shares: 747,200


Exercise Price January 2025 Common Warrants: $3.855


Exercise Price February 2025 Warrants: $2.95


Exercise Price January 2025 Placement Agent Warrants: $6.382


Exercise Price February 2025 Placement Agent Warrants: $4.469


Stock Split Ratio: 1-for-5


Trading Symbol: SXTP


Closing Price Stock: $1.88


Market Estimation Accessible Market For Arakoda: 330,000 prescriptions


Estimated Cases For Chronic Babesiosis: 375,000 cases


Reported Cases Of Candidiasis: 50,000 cases


Reported Cases Of C Auris: 1,900 cases


Form Type: S-1

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000121390025014334

Filing Summary: 60 Degrees Pharmaceuticals, Inc. filed a registration statement on Form S-1 with the United States Securities and Exchange Commission on February 14, 2025. The filing indicates the intention to conduct a public offering of up to 3,735,977 shares of common stock at a par value of $0.0001 per share. The common stock is being offered by selling stockholders, and the registration includes shares issuable upon the exercise of various warrants acquired in recent private placements. Key details include: 2,043,098 shares from January 2025 Common Warrants at an exercise price of $0.771, and 1,503,500 shares from February 2025 Common Warrants at $0.59. The registration statement is filed pursuant to the Securities Act of 1933, with the aim of immediately reselling the shares once the registration is effective. The company has stated it will not receive any proceeds from the sale of shares by selling stockholders, but it anticipates receiving approximately $1.5 million from exercise of the warrants by the selling stockholders. The company is categorized as a smaller reporting and emerging growth company under the JOBS Act. The prospectus highlights growth opportunities in the malaria prevention market and positions the company for potential future treatments for tick-borne and fungal diseases, leveraging existing products and research in development.

Additional details:

State Of Incorporation: Delaware


Irs Employer Identification No: 45-2406880


Primary Sic Code: 2834


Number Of Shares Registered: 3735977


Type Of Common Stock: common


Total Proceeds From Exercises: 2591867


Comments

No comments yet. Be the first to comment!